Felix Breden (Canada), 2013
John Hammond (UK), 2020
- Eva Bengtén (USA) 2006
- Salvatrice Ciccarese (Italy) 2007
- Deborah Dunn‐Walters (UK) 2006
- Jean‐Pol Frippiat (France) 2006
- Véronique Giudicelli (France) 2014
- Sofia Kossida (France) 2014
- Ramit Mehr (Israel) 2017
- Serge Muyldermans (Belgium) 2006
- John Schwartz (UK) 2020
- Jamie Scott (Canada) 2013
- Corey T. Watson (USA) 2013
The IG/TR/MH Sub-committee adopted Terms of Reference in Spring 2022 outlining a democratic and transparent governance structure. The following description of the Sub-committee’s goals, structure, and processes will be revised over the next several months as it responds to changes in the quantity and types of data available for understanding IG and TR germline gene polymorphisms, and as the Sub-committee strives to best serve the immunogenetics community.
In continuing the pioneering work of Dr. Marie-Paule Lefranc, the IG/TR/MH Nomenclature Sub-committee is responsible for validating, approving, and assigning names to newly discovered immunoglobulin (IG) and T-cell receptor (TR) germline genes and non-human MHC genes (MH), following the principles of the IMGT™ information system insofar as possible. This Sub-committee is also responsible for coordinating the biocuration of these genes in the appropriate germline gene database (e.g., IMGT).
The IG/TR/MH Nomenclature Sub-committee will practice in its governance and its partnerships:
- Excellence and professionalism
- Inclusivity and diversity
- Transparency and integrity
- Innovation and sustainability
Terms of Reference
Click here to access the terms of reference for this Sub-committee
Reports to IUIS.
You will find information about the history of the Sub-Committee since its creation and annual reports through the 17th International Congress of Immunology in 2019 here:
IMGT-NC Reports Review Committee
IMGT-NC Reports is a Review Committee of the IUIS IG/TR/MH Nomenclature Sub-Committee. It evaluates, names and reports new germline genes encoding immunoglobulins (IG), T-cell receptors (TR). Scientists submit sequences for new IG and TR variable (V), diversity (D), joining (J) and constant (C) genes and alleles to the IMGT-NC Reports Review Committee. The gene sequences must: (1) be derived from genomic DNA (2) include RSS flanking regions, (3) be an allele of a gene whose position is known in the corresponding IG or TR locus assembly. Working with the Scientist, Members of this Review Committee review and approve sequences and provide names, based on the IMGT Scientific chart rules and the IMGT-ONTOLOGY concepts of classification (CLASSIFICATION axiom) where applicable. Validated IG and TR germline gene sequences and their names are passed to IMGT for biocuration and addition to its database.
NOTE: The IMGT NC Reports Review Committee is currently transitioning from an unelected body to an elected one. Membership will be posted here on completion of the election.
Inferred Allele Review Committee
IG and TR germline V gene sequences can also be deduced from next-generation sequencing data from a B- or T-cell receptor repertoire. The Inferred Allele Review Committee (IARC) is a committee of the Adaptive Immune Receptor Repertoire (AIRR) Community Committee of The Antibody Society whose mission is to validate human IG and TR germline V gene allelic sequences that have been inferred from next-generation sequencing data. Criteria required for an inferred V allele to be considered for validation include (1) deposition of the repertoire from which the inference was made in the NCBI or ENA and in a peer-reviewed publication, (2) the complete V coding region, (3) inferences made with a validated and publicly available tool published in a peer-reviewed publication. Working with the IMGT-NC Reports Review Committee, validated gene sequences are named and added to the IMGT-NC Report.
Guidelines for submitting inferred allele sequences to the IARC can be found here.
Mats Ohlin (Sweden), Chair
Current public databases containing IG and TR germline-gene sequences and reference sets.